THE RELATIONSHIP BETWEEN CARDIAC RESYNCHRONİZATION THERAPY RESPONSE IN HEART FAILURE PATIENTS AND YKL-40 LEVELS

Patients diagnosed with heart failure at our clinic who routinely undergo CRT implantation will be included in the study. This decision is independent of the study. In patients included in the study, after routine placement of a coronary sinus catheter, 2 cc of blood will be drawn from this catheter without performing any additional invasive procedures on the patient. Additionally, one peripheral blood sample will be collected from the patient's routinely accessed antebrachial vein. The blood samples will be centrifuged at 4000 rpm (revolutions per minute) for 10 minutes to separate the serum and stored at -80 °C until analyzed. The demographic, clinical, laboratory, electrocardiographic, and echocardiographic data of these patients will be recorded. At the 6-month follow-up clinic visit after discharge, routine heart failure parameters, routine echocardiographic data, and routine ECG recordings will be obtained. The procedures to be performed after discharge are routine for patients who have undergone CRT implantation at our clinic, and no additional follow-up or tests will be performed for this study. After all data are recorded, statistical evaluation will be performed. Data will be reviewed through the ENLİL HBYS system. The best criteria for determining CRT response have not been clearly established. Many studies have been conducted to predict CRT response in advance. A review of the literature shows that YKL-40 levels in the blood are associated with cardiovascular diseases, but no study in the literature has shown the relationship between YKL-40 levels and CRT implantation in patients.

NCT Number	NCT07469137
Lead Sponsor	Trakya University
Conditions	Hearth Failure With Reduced Ejection Fraction (HFrEF), Cardiac Resynchronisation Therapy (CRT), Left Branch Bundle Block
Enrollment	51 participants
Start Date	2025-03-01
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-13